Sharp Therapeutics Corp.SHRX.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · United States
Sharp Therapeutics Corp. is a preclinical-stage drug discovery company developing small molecule therapeutics for genetic diseases, headquartered in Pittsburgh, Pennsylvania. The company's CoreX technology suite and AlloChem compound library target compounds that correct mutational defects in diseases such as Gaucher's disease and Niemann-Pick Type C.
Key ratios
ROA
-131.6%TTM
2025
-105.9%2024
-52.1%2023
-95.6%
ROE
-3762.2%TTM
2025
-512.8%
Recent news
Sharp Therapeutics Corp. Reports First Half 2026 Results and Development Update
Sharp Therapeutics Announces Closing of Non-Brokered Private Placement
Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders
Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update
Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date
Sharp Therapeutics Presents New Preclinical Data Supporting Novel Small-Molecule Therapeutic Approach for Niemann-Pick Disease Type C
Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Track SHRX.V in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer